Executive Summary

4.2 USD Billion in 2025, the Remote Cardiac Monitoring Market is expected to grow at a CAGR of 10.61% to reach 11.6 USD Billion by 2035.

Reimbursement expansion is the clearest demand mechanism: Medicare payments for remote patient monitoring reached USD 536 million in 2024, a 31% increase over 2023, per the HHS Office of Inspector General. Device makers are pairing wearable ECG patches and implantable loop recorders with monitoring-center services to capture this billing pathway.

North America held 42.0% of the market in 2025, ahead of Asia Pacific at 27.0% and Europe at 19.0%. Devices remained the leading product category, with homecare settings the leading end-use environment.

EU MDR-aligned interoperability obligations under the European Health Data Space Regulation add compliance cost for vendors moving ECG data across borders. Uneven hospital AI-governance capacity tempers how quickly analytics-heavy monitoring platforms scale into reimbursed care.

Key Takeaways

• A CAGR of 10.61% carries the market from USD 4.22 Billion in 2025 to USD 11.57 Billion in 2035.
• On product, the leading category is Devices.
• Homecare Settings holds the largest position on end user.
• 42.0% of 2025 revenue was earned in North America.
• 10 suppliers are profiled.

Market Definition and Scope

The Remote Cardiac Monitoring Market covers wearable and implantable devices, including implantable cardiac monitors, Holter monitors, mobile cardiac telemetry devices, event monitors and cardiac rhythm management devices such as pacemakers, ICDs and CRT devices, together with the diagnostic and analytics software and remote monitoring, interpretation and technical-support services that transmit and process a patient’s cardiac electrical activity for hospital, emergency and homecare use.

The boundary excludes general consumer fitness wearables that log heart rate without diagnostic-grade ECG output, and standalone electronic health record systems that store rather than actively transmit cardiac telemetry.

Market Trends

Medicare’s remote patient monitoring pathway is pulling cardiac telemetry into routine care

Medicare payments for remote patient monitoring rose to USD 536 million in 2024, a 31% increase over 2023, with enrollees receiving RPM services up 27% to nearly one million, per the HHS Office of Inspector General’s August 2025 report. As more of the 10,388 billing practices routinize claims, cardiology providers are shifting Holter and mobile cardiac telemetry follow-up from in-clinic visits to home-based transmission, extending device and monitoring-service demand through the forecast period.

Hospitals are building AI governance capacity before scaling analytics-heavy monitoring platforms

In 2024, 82% of US hospitals evaluated predictive AI models for accuracy and 74% for bias, but only 71% and 57% did so across all or most models, and 15% could not say whether accuracy evaluation happened at all, per ASTP/ONC’s 2024 hospital AI data brief. Vendors of arrhythmia-detection and analytics software are responding by building bias-testing and post-implementation monitoring into their platforms, since a hospital’s governance capacity, not algorithm performance, determines how quickly it approves routine use.

Regulatory sandboxes are setting the terms for cross-border AI-enabled monitoring

The UK’s MHRA moved its AI Airlock sandbox for AI-as-a-medical-device into a second phase running April 2025 to March 2026, backed by a GBP 3.6 million three-year commitment, while the EU’s European Health Data Space Regulation entered into force in March 2025 to set interoperability rules for cross-border ECG and telemetry data. Vendors selling monitoring software into both jurisdictions must now sequence clinical validation against two separate frameworks, pushing multi-market rollouts of AI-enabled monitoring software later into the forecast period.

Growth Drivers and Restraints

Medicare reimbursement expansion is converting pilot programs into routine billing

Medicare RPM payments reached USD 536 million in 2024, a 31% increase over 2023, and nearly one million enrollees received RPM services, up 27% year on year, per the HHS Office of Inspector General’s August 2025 report. CMS’s CPT and HCPCS remote-monitoring billing codes make monitoring-center staffing and interpretation services reimbursable on a recurring basis, and homecare-based cardiac monitoring is absorbing the largest share of the resulting device and service volume; 10,388 practices billed at least one RPM service in 2024.

AI-enabled arrhythmia detection is shifting value from hardware to the software layer

The European Health Data Space Regulation, in force since March 2025, sets a common EU interoperability framework that lets diagnostic and analytics software vendors move ECG and telemetry data across member states inside one compliance model rather than 27 separate ones. The UK’s MHRA has run its AI Airlock sandbox for AI-as-a-medical-device through a second phase from April 2025 to March 2026, giving arrhythmia-detection software developers a structured route to evidence generation ahead of full market authorization; the shift favors software and connectivity-platform revenue within the wider device-led market.

Physician-in-the-loop mandates are keeping data-interpretation services central to the revenue mix

Brazil’s CFM Resolution No 2,454/2026, issued in February 2026, bars AI systems from autonomously communicating a cardiac diagnosis and requires a licensed physician to sign off on every AI-assisted read, with the treating institution carrying oversight responsibility. That kind of mandated human review sits on top of a reimbursement base that already routed 10,388 US practices into Medicare’s remote-monitoring billing pathway in 2024, and it keeps staffed data-interpretation and reporting services central to the commercial model rather than ceding volume to self-reading software.

Uneven hospital AI governance is slowing adoption of the highest-value monitoring software

In 2024, only 71% of US hospitals evaluating predictive AI models checked accuracy across all or most of them, only 57% did so for bias, and 15% could not say whether accuracy evaluation happened at all, per ASTP/ONC’s 2024 hospital AI data brief. Facilities without established validation and monitoring workflows are approving arrhythmia-detection software more slowly than device procurement alone would suggest, concentrating near-term analytics revenue in larger health systems that already run formal model-governance committees.

India’s local revalidation requirement raises the cost and timeline of Asia Pacific market entry

India’s final CDSCO software guidance for medical device software requires that AI and machine-learning models trained outside India be justified for Indian clinical settings and revalidated against representative Indian patient populations, with continuous post-market monitoring for drift, bias and hallucination. For monitoring-software vendors that built their evidence base on US or EU patient data, the rule adds a distinct validation cycle before Indian hospitals can deploy the same product, delaying the region’s contribution to software and services revenue relative to device sales.

Regional Analysis

North America

North America is the largest regional market, at 42.0% of 2025 revenue and USD 1.77 Billion.

Asia Pacific

The second-largest regional market, Asia Pacific accounted for 27.0% in 2025 and USD 1.14 Billion.

Europe

19.0% of 2025 revenue was earned here, or USD 0.80 Billion.

Segment Analysis

By Product

• Devices (largest) – Wearable or implantable hardware such as ECG patches, loop recorders, and pacemaker/ICD monitors that capture a patient’s cardiac electrical activity for transmission to clinicians

• Implantable Cardiac Monitors
• Holter Monitors
• Mobile Cardiac Telemetry (MCT) Devices
• Event Monitors
• Cardiac Rhythm Management Devices

• Pacemakers
• Implantable Cardioverter Defibrillators (ICDs)
• Cardiac Resynchronization Therapy (CRT) Devices
• Software – Platforms that receive, analyze, and display transmitted cardiac data, flagging arrhythmias and generating reports for physician review

• Diagnostic & Monitoring Software
• Data Analytics & AI Software
• Connectivity & Integration Platforms
• Services – Support offerings including device implantation, data monitoring center staffing, technical support, and subscription-based patient management that accompany remote cardiac monitoring programs

• Remote Monitoring Services
• Data Interpretation & Reporting Services
• Technical Support & Maintenance Services

Devices led the product mix in 2025, ahead of software and services. Remote cardiac monitoring programs begin with a physical sensor: wearable ECG patches, implantable loop recorders, mobile cardiac telemetry units and pacemaker or ICD hardware generate the raw electrical signal that every downstream software and service layer depends on. Hospitals and cardiology groups standardize purchasing around device platforms carrying established reimbursement coding, and replacement or upgrade cycles on an installed device base keep hardware spend recurring even as programs mature. Software is expanding fastest as monitoring programs generate denser data streams. Rising patient volumes under remote patient monitoring reimbursement are pushing diagnostic and AI-based analytics software, and connectivity and integration platforms, from a bundled add-on toward a distinct purchasing line as providers work to triage arrhythmia alerts and manage growing caseloads at scale.

By End User

• Hospitals & Clinics – Inpatient and outpatient facilities where cardiologists and clinicians order and interpret remote cardiac monitoring for diagnosis and post-procedure follow-up

• Hospitals
• Cardiology Clinics
• Ambulatory Surgical Centers
• Emergency Settings – Ambulances, emergency departments, and urgent care units that use remote cardiac monitoring to detect arrhythmias and guide immediate triage decisions

• Emergency Medical Services (EMS)
• Emergency Departments
• Homecare Settings (largest) – Patients’ residences where wearable or implantable devices transmit cardiac data to remote monitoring platforms for ongoing outpatient disease management

• Home Healthcare Agencies
• Independent/Self-Monitoring Patients
• Others – Ambulatory surgical centers, rehabilitation facilities, sports medicine clinics, and research institutions that apply remote cardiac monitoring outside standard clinical or home environments

Homecare settings led end use in 2025, ahead of hospitals and clinics, emergency settings and other outpatient sites. Wearable and implantable devices let patients transmit cardiac data from home rather than during an inpatient stay, and expanding reimbursement for remote patient monitoring has made continuous, outpatient surveillance billable rather than a self-funded add-on for chronic arrhythmia and post-implant management. Hospitals and clinics are the quickest-growing setting, pulled by post-procedure follow-up protocols and a fast-rising base of practices now billing remote monitoring services. Cardiology groups are extending device-based surveillance beyond the immediate post-implant window into longer ambulatory follow-up, widening the clinic-billed share of monitoring episodes as caseloads shift outside the hospital ward.

Competitive Landscape

The remote cardiac monitoring market is led by a group of established medical device and diagnostics manufacturers rather than a single dominant supplier. Competition centers on regulatory clearance breadth under the FDA’s 510(k) and De Novo pathways for device and software claims, reimbursement coding for remote monitoring and interpretation services billed against CMS’s remote physiologic monitoring CPT and HCPCS codes, an installed device base with recurring consumable and subscription pull-through, and long-term contracts with hospital systems and cardiology groups. Devices sold into the European Union must additionally clear the EU MDR, patient data captured by ambulatory monitors and patches falls under HIPAA in the United States, and software validation and electronic-record controls under 21 CFR Part 11 apply to the AI-assisted detection algorithms increasingly embedded in these platforms. Key players include Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Nihon Kohden Corporation, OSI Systems, Inc., iRhythm Technologies, Inc. and Honeywell International Inc.

iRhythm Technologies launched its Zio Long-Term Continuous Monitoring service in Japan in May 2025, extending AI-assisted arrhythmia detection into the world’s second-largest ambulatory cardiac monitoring market and widening the addressable base for continuous ECG patch adoption outside the United States. iRhythm also agreed in August 2026 to acquire VitalConnect, adding a multi-parameter biosensor platform spanning ambulatory, inpatient and hospital-to-home settings and positioning the combined company across a broader continuum of remote cardiac and vital-sign monitoring. The FDA cleared Apple’s Hypertension Notification Feature under a Class II cardiovascular software pathway in September 2025, an approval that signals consumer wearables are now entering the same regulatory lane as clinical-grade cardiac monitoring devices.

Strategic Outlook

The clearest whitespace sits in decentralized, software-layered monitoring across Asia Pacific’s ambulatory base, where a large existing test volume in markets such as Japan gives device and platform vendors a population to convert to continuous, AI-assisted arrhythmia detection rather than build from nothing. That conversion depends on regulators and payers extending coverage for remote interpretation, not just for the sensor itself.

By 2035, competitive weight should keep moving from device placement toward the software and services that interpret continuous data streams, as hospital-to-home platforms consolidate ambulatory, inpatient and homecare monitoring into a single vendor relationship rather than separate point solutions.

Remote Cardiac Monitoring Market Report Scope